![Heather Raymon](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 1 M $ al 31/05/2026
Heather Raymon currently works at Artiva Biotherapeutics, Inc., as Senior VP-Research & Early Development from 2023.
Dr. Raymon also formerly worked at Bristol Myers Squibb Co., as Executive Director-Early Development Program and Celgene Corp., as Senior Director & Head-Pharmacology.
Dr. Raymon received her undergraduate degree from State University of New York at Albany and doctorate degree from the University of California, Irvine.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 19/05/2026 | 148.228 ( 0,31 % ) | 1 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ARTIVA BIOTHERAPEUTICS, INC. | Corporate Officer/Principal | 01/10/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
State University of New York at Albany
 State University of New York at Albany Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Irvine
 University of California, Irvine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
